The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis?
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index; 125 of the 161 sources its claims cite were checked for support.
Abstract
A strong genetic predisposition (60-80% of attributable risk) is present in Alzheimer's disease (AD). In view of this major genetic component, identification of the genetic risk factors has been a major objective in the AD field with the ultimate aim to better understand the pathological processes. In this review, we present how the genetic risk factors are involved in APP metabolism, β-amyloid peptide production, degradation, aggregation and toxicity, innate immunity, and Tau toxicity. In addition, on the basis of the new genetic landscape, resulting from the recent high-throughput genomic approaches and emerging neurobiological information, we propose an over-arching model in which the focal adhesion pathway and the related cell signalling are key elements in AD pathogenesis. The core of the focal adhesion pathway links the physiological functions of amyloid precursor protein and Tau with the pathophysiological processes they are involved in. This model includes several entry points, fitting with the different origins for the disease, and supports the notion that dysregulation of synaptic plasticity is a central node in AD. Notably, our interpretation of the latest data from genome wide association studies complements other hypotheses already developed in the AD field, i.e., amyloid cascade, cellular phase or propagation hypotheses. Genetically driven synaptic failure hypothesis will need to be further tested experimentally within the general AD framework.
Overview
CoChat Summary
TL;DR
This review synthesizes the post-GWAS genetic landscape of Alzheimer’s disease and argues that, beyond amyloid, many risk genes converge on the focal adhesion pathway and synaptic function. It proposes a “genetically driven synaptic failure” hypothesis in which APP, Tau, focal adhesion signaling, and Aβ toxicity form a circular, multi-entry model of AD pathogenesis.
Key findings
- AD has a strong genetic predisposition, estimated at 60–80% of attributable risk; APOE alone accounts for about 20%, and more than 45 genes/loci have been associated with AD risk, while monogenic forms represent less than 1% of cases.
- Post-GWAS genes support the amyloid cascade through APP metabolism/Aβ production (e.g., ADAM10, APH1B, BIN1, CD2AP, PICALM, ABCA7, SORL1), Aβ clearance (ApoE, CLU, PICALM, ABCA7, CR1, TREM2, CD33), and Aβ toxicity, with microglia implicated in clearance and plaque compaction.
- Many GWAS-defined genes also modulate Tau toxicity and belong to the focal adhesion pathway (e.g., CASS4, PTK2B, EPHA1, MADD, CD2AP, FERMT2, CELF1, TLN2; BIN1 interacts with FAK/F-actin), linking APP and Tau to synaptic dynamics.
- The authors propose an over-arching circular model in which focal adhesion/synaptic dysfunction is central, Aβ is sufficient but not necessary, and multiple entry points—APP/Tau dysfunction, Aβ toxicity, microglial dysfunction—can drive synaptic failure and cognitive decline.
Methods
- Narrative review; no primary experimental data are reported.
- Synthesizes AD genetics literature, including GWAS, next-generation sequencing, and post-GWAS functional studies in cellular and animal models (e.g., Drosophila, mouse, C. elegans), plus pathway and expression analyses.
- Main analysis integrates genetic risk loci with APP/Aβ biology, Tau pathology, microglial function, focal adhesion signaling, and synapse dynamics to propose the genetically driven synaptic failure model.
Limitations
- The authors state that GWAS-defined genes were initially characterized mainly in models built around the amyloid cascade hypothesis, creating bias, potential tautological reasoning, and a priori exclusion of other pathways; gene functions are often incompletely understood, and for some loci the responsible gene is difficult or impossible to assign due to multiple genes and complex linkage disequilibrium.
- The authors note that a large part of AD’s genetic component remains unknown and that the proposed synaptic failure hypothesis requires further experimental testing.
- Evident from the text: this is a review and interpretive synthesis, not a primary study; some supporting evidence is preliminary or unpublished (e.g., Kindlin-2 localization), and data linking many GWAS genes to synapses and Tau remain limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Circular diagram of AD genetic risk factors. The diagram shows (from outside to inside): (1) genomic loci in alphabetical order; (2) genes therein; (3) expression profiles of these genes in different cell types of the brain (grayscale); and (4) the pathways/processes/proteins to which these genes have been functionally linked (colour). Details of the functional studies supporting these linkages are available in Suppl. Table. Expression profiles were extracted from [155] (FPKM fragments per kilobase of transcript sequence per million mapped fragments). The circlize package of the R software (http://www.r-project.org/) was used to generate the diagram [38]](https://figures.cochat.ai/paper-figures/8e3b688d36ae43b0b02c9a6bde97207f/the-new-genetic-landscape-of-alzheimers-disease-from-amyloid-cascade-to-figure-1.jpg)




Verification
Claims the paper makes
86 Valid · 7 Not valid · 21 Not checked · 47 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Accordingly, APP–integrin interaction is required for neurite outgrowth and contact guidance [123, 153].”
§ The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? > Beyond Aβ peptides and the APP metabolism > APP’s role in synaptic function and AD-related synaptic dysfunction
What the sources say
- Disputedcites [123] Sosa LJ Bergman J Estrada-Bernal A Glorioso TJ Kittelson JM Pfenninger KH Amyloid precursor protein is an autonomous growth cone adhesion molecule engaged in contact guidance PLoS One 2013 8 e64521 10.1371/journal.pone.0064521 23691241 PMC3653867 sourceExperimental — accuracy not yet measured
In the Discussion section “Determining APP-Mediated Adhesion” (page unavailable), the paper says APP-mediated adhesion alone can sustain neurite outgrowth and that APP–integrin complexes are not necessary for adhesion; it says their functional role remains unknown. The Results section “APP Influences Axonal Contact Guidance” reports effects of APP expression and integrin knock-down on substrate choice, not a requirement for their interaction. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [153] Young-Pearse TL Chen AC Chang R Marquez C Selkoe DJ Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1 Neural Dev 2008 3 15 10.1186/1749-8104-3-15 18573216 PMC2442059 sourceExperimental — accuracy not yet measured
The Results show that APP interacts with integrin β1 and that blocking integrin β1 abolishes the neurite-outgrowth increase seen in APP-knockout or APPs-α-treated neurons. They do not establish that APP–integrin interaction is required for neurite outgrowth generally: the blocking antibody had no significant effect on neurite length in wild-type neurons. Our copy does not report a contact-guidance result (searched: contact guidance). (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Together, these genetic analyses have pointed out more than 45 genes/loci associated with the risk of developing AD even if it is estimated that a large part of the genetic component of AD is still unknown [103].”
§ The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? > Genetic landscape of AD
What the sources say
- Partly supportedcites [103] Ridge PG Hoyt KB Boehme K Mukherjee S Crane PK Haines JL Assessment of the genetic variance of late-onset Alzheimer’s disease Neurobiol Aging 2016 41 200.e13 200.e20 10.1016/j.neurobiolaging.2016.02.024 PMC4948179 27036079 sourceExperimental — accuracy not yet measured
The Introduction reports more than 20 distinct AD-associated loci and additional rare variants in several genes, but does not establish the claimed count of more than 45 genes or loci. The Conclusions state that 69% of genetic variance remains unexplained, supporting the citing sentence’s separate point about the unknown genetic component. No page numbers are available in our copy. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, despite these effects on Aβ production in vitro, deleting a single BIN1 or CD2AP allele did not modify amyloid deposition in mouse models of AD [2, 87].”
§ The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? > The post-GWAS era and the amyloid cascade hypothesis > APP metabolism and Aβ peptide production
What the sources say
- Supportedcites [2] Andrew RJ De Rossi P Nguyen P Kowalski HR Recupero AJ Guerbette T Reduction of the expression of the late-onset Alzheimer’s disease (AD) risk-factor BIN1 does not affect amyloid pathology in an AD mouse model J Biol Chem 2019 294 4477 4487 10.1074/jbc.ra118.006379 30692199 PMC6433054 source
The Discussion reports that deletion of a single Bin1 allele reduced BIN1 protein by 50% and did not alter cerebral Aβ deposition in an AD mouse model. The CD2AP finding is not attributed specifically to this BIN1 paper in the sentence with two citations. (LLM, conf=0.93)
- Supportedcites [87] Liao F Jiang H Srivatsan S Xiao Q Lefton KB Yamada K Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model Mol Neurodegener 2015 10 12 10.1186/s13024-015-0006-y 25887956 PMC4374406 source
The Results and discussion section (page not supplied) reports that PS1APP mice with one CD2AP allele had no difference in cortical Aβ plaque load at 7 months. This supports the CD2AP part of the sentence; the separate BIN1 citation is not assessed here. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“since the seminal GWAS papers published in 2009 [47, 83], more than 30 loci of interest have been identified to be associated with AD risk (Suppl. Table) [50, 59, 67, 76, 84, 97, 116, 120].”
§ The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? > Genetic landscape of AD
What the sources say
- Supportedcites [47] Harold D Abraham R Hollingworth P Sims R Gerrish A Hamshere ML Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease Nat Genet 2009 41 1088 1093 10.1038/ng.440 19734902 PMC2845877 source
The cited work is one of the 2009 GWAS papers identified in the sentence. Its Abstract reports a genome-wide association study that found AD-risk associations at CLU and PICALM. The claim that more than 30 loci were identified subsequently is attached to the sentence’s later citations, not to this paper. (LLM, conf=0.91)
- Supportedcites [83] Lambert J-C Heath S Even G Campion D Sleegers K Hiltunen M Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease Nat Genet 2009 41 1094 1099 10.1038/ng.439 19734903 source
The citation to this source is attached to “the seminal GWAS papers published in 2009,” not to the later count of more than 30 loci, which has separate citations. The paper’s Abstract describes its Alzheimer’s disease GWAS and reports associations at CLU and PICALM, so it supports its identification as a 2009 GWAS paper. (LLM, conf=0.93)
- Partly supportedcites [50] Hollingworth P Harold D Sims R Gerrish A Lambert J-C Carrasquillo MM Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease Nat Genet 2011 43 429 435 10.1038/ng.803 21460840 PMC3084173 sourceExperimental — accuracy not yet measured
The Abstract reports five novel AD susceptibility genes, supporting this paper’s inclusion among studies identifying risk loci after the 2009 GWAS papers. It does not establish the sentence’s aggregate claim that more than 30 loci had been identified; that total is attributed to a group of citations, not demonstrated by this paper alone. (LLM, conf=0.88)
- Supportedcites [59] Jansen IE Savage JE Watanabe K Bryois J Williams DM Steinberg S Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk Nat Genet. 2019 51 3 404 413 10.1038/s41588-018-0311-9 30617256 PMC6836675 source
The Results (Genome-wide meta-analysis for AD status; page unavailable) report 29 associated loci, including 13 not identified in Lambert et al.’s earlier set of 20 regions. Together, those findings support more than 30 loci identified as being of interest for AD risk, although the paper notes that some earlier associations were not replicated. (LLM, conf=0.85)
- Partly supportedcites [67] Jun G Ibrahim-Verbaas CA Vronskaya M Lambert J-C Chung J Naj AC A novel Alzheimer disease locus located near the gene encoding Tau protein Mol Psychiatry 2015 10.1038/mp.2015.23 25778476 PMC4573764 sourceExperimental — accuracy not yet measured
The Results report a newly identified genome-wide significant AD risk locus near MAPT, so this paper supports one example among the cited discoveries. It does not state that more than 30 loci had been identified since the 2009 GWAS papers; the count is not supported by this source alone. (LLM, conf=0.84)
- Partly supportedcites [76] Kunkle BW Grenier-Boley B Sims R Bis JC Damotte V Naj AC Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, Tau, immunity and lipid processing Nat Genet 2019 51 414 430 10.1038/s41588-019-0358-2 30820047 PMC6463297 sourceExperimental — accuracy not yet measured
The Results (Meta-analysis of Alzheimer’s disease GWAS; page unavailable) report previously known associations and identify new Alzheimer’s disease risk loci. The paper supports the claim that loci continued to be identified after the 2009 GWAS papers, but its discussion of 24 associated loci does not establish the cited sentence’s total of more than 30. (LLM, conf=0.84)
- Partly supportedcites [84] Lambert JC Ibrahim-Verbaas CA Harold D Naj AC Sims R Bellenguez C Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease Nat Genet 2013 45 1452 1458 10.1038/ng.2802 24162737 PMC3896259 sourceExperimental — accuracy not yet measured
The paper reports 19 loci reaching genome-wide significance in the combined analysis, in addition to APOE (Abstract; page unavailable). It also reports 13 further loci with only suggestive evidence of association (Abstract; page unavailable). Together these exceed 30 loci of interest, but the source does not establish all of them as associated with Alzheimer’s disease risk. (LLM, conf=0.84)
- Partly supportedcites [97] Naj AC Jun G Beecham GW Wang L-S Vardarajan BN Buros J Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease Nat Genet 2011 43 436 441 10.1038/ng.801 21460841 PMC3090745 sourceExperimental — accuracy not yet measured
The paper’s Abstract reports genome-wide significant associations at four late-onset Alzheimer’s disease loci, supporting this source’s contribution to the citing sentence’s list. It says there were ten known susceptibility loci at the time, however, so this paper does not establish the cumulative claim of more than 30 loci since 2009. (LLM, conf=0.86)
- Partly supportedcites [116] Seshadri S Fitzpatrick AL Ikram MA DeStefano AL Gudnason V Boada M Genome-wide analysis of genetic loci associated with Alzheimer disease JAMA 2010 303 1832 1840 10.1001/jama.2010.574 20460622 PMC2989531 sourceExperimental — accuracy not yet measured
The Results section reports several AD-associated loci, including two novel loci on chromosomes 2 and 19, so this paper supports the citation as an example of loci identified after the 2009 GWAS papers. It does not support the sentence’s aggregate count of more than 30 loci. (LLM, conf=0.88)
- Partly supportedcites [120] Sims R van der Lee SJ Naj AC Bellenguez C Badarinarayan N Jakobsdottir J Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease Nat Genet 2017 49 1373 1384 10.1038/ng.3916 28714976 PMC5669039 sourceExperimental — accuracy not yet measured
The paper states that nearly 30 late-onset AD susceptibility loci were known and reports additional associated variants in PLCG2, ABI3 and TREM2 (opening text and Abstract; page not specified). It does not establish the citing sentence’s count of more than 30 loci. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“More recently, PICALM has been described in vitro and in vivo to participate to Aβ transcytosis and clearance at the BBB through clathrin-dependent internalisation of Aβ after its binding to the LDLR-related protein-1 [157].”
§ The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? > The post-GWAS era and the amyloid cascade hypothesis > Aβ peptide degradation/clearance
What the sources say
- Supportedcites [157] Zhao Z Sagare AP Ma Q Halliday MR Kong P Kisler K Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance Nat Neurosci 2015 18 978 987 10.1038/nn.4025 26005850 PMC4482781 source
The Results section on PICALM/clathrin-dependent endocytosis states that Aβ binding to LRP1 initiates endocytosis of the Aβ–LRP1 complex. The Introduction identifies endothelial PICALM as central to Aβ clearance and transcytosis across the BBB, and the Results report transendothelial transport of the internalized complex. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
100 more claims · 60 with their cited sources checked
Create a free account to see all 161 claims and to verify the 3 references still open.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 17
- Not yet classified. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“emphasizing that ADD results from complex crosstalk between different cell types in the brain23,40.”
From New insights into the genetic etiology of Alzheimer’s disease and related dementias (2022) · cites this paper as [23]
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 10×
“CD2AP [95, 108, 138, 144, 184] CD2AP CD2 associated protein, scaffolding protein involved in the regulation of membrane receptor endocytosis and signaling, actin cytoskeleton organization, endosomal vesicular trafficking, cell adhesion and cytokinesis [47, 61, 83, 116, 137, 157, 291] -its loss-of-function raises Aβ ge…”
BackgroundInfluentialSelf-citationcirclize implements and enhances circular visualization in R
Gu, Z., Gu, L., Eils, R., Schlesner, M., & Brors, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu393 · Cited by 4,246 · cited 1×
“org/) was used to generate the diagram [38] ◂”
MethodComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 1×
“It is also suspected that perturbations in homeostatic microglia functions at synapses may lead to early synapse loss in an Aβ-dependent or potentially independent manner [52, 93].”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“1); and (4) a major genetic discovery indicated that non-synonymous variants in TREM2, ABI3 and PLCγ2 were associated with AD risk [40, 65, 120].”
BackgroundSelf-citationAlzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946 · cited 1×
“Very recent GWASs have strengthened the importance of APP metabolism by directly pointing out two of its main actors as AD genetic risk factors: ADAM10, which carries out the main α-secretase activity in the brain, and APH1B, which is part of the γ-secretase complex [59, 76].”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“1); and (4) a major genetic discovery indicated that non-synonymous variants in TREM2, ABI3 and PLCγ2 were associated with AD risk [40, 65, 120].”
BackgroundZhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., Vogel, H., Steinberg, G. K., Edwards, M. S. B., Li, G., et al. (2016) · Neuron · doi:10.1016/j.neuron.2015.11.013 · Cited by 2,295 · cited 1×
“Expression profiles were extracted from [155] (FPKM fragments per kilobase of transcript sequence per million mapped fragments).”
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277 · cited 2×
“Very recent GWASs have strengthened the importance of APP metabolism by directly pointing out two of its main actors as AD genetic risk factors: ADAM10, which carries out the main α-secretase activity in the brain, and APH1B, which is part of the γ-secretase complex [59, 76].”
Background
Research works printed but not linked: 2
- Guerreiro R Wojtas A Bras J Carrasquillo M Rogaeva E Majounie E TREM2 variants in Alzheimer’s disease N Engl J Med 2013 368 117 127 10.1056/nejmoa1211851 23150934 PMC3631573 · DOI · Paper page
- Jones L Lambert J-C Wang L-S Choi S-H Harold D Vedernikov A Convergent genetic and expression data implicate immunity in Alzheimer’s disease Alzheimer’s Dement 2015 11 658 671 10.1016/j.jalz.2014.05.1757 25533204 PMC4672734 · DOI · Paper page
Cited by
New insights into the genetic etiology of Alzheimer’s disease and related dementias
Bellenguez, C., Küçükali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01024-z · Cited by 2,498
Self-citationCellular functions of the protein kinase ATM and their relevance to human disease
Lee, J.-H., & Paull, T. T. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00394-2 · Cited by 289
Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer’s Disease
Sharma, C., Kim, S., Nam, Y., Jung, U. J., & Kim, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094850 · Cited by 234
Dysfunctional Mitochondria and Mitophagy as Drivers of Alzheimer’s Disease Pathogenesis
Chakravorty, A., Jetto, C. T., & Manjithaya, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00311 · Cited by 219
Genetics of Alzheimer’s disease: where we are, and where we are going
Bellenguez, C., Grenier-Boley, B., & Lambert, J.-C. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.024 · Cited by 215
Self-citationMicroglial Phagocytosis: A Disease-Associated Process Emerging from Alzheimer’s Disease Genetics
Podleśny-Drabiniok, A., Marcora, E., & Goate, A. M. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.10.002 · Cited by 211
Targeting neuroinflammation in Alzheimer’s disease: from mechanisms to clinical applications
Liu, Y., Si, Z.-Z., Zou, C.-J., Mei, X., Li, X.-F., Luo, H., Shen, Y., Hu, J., Li, X.-X., & Wu, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.353484 · Cited by 182
“The new avenues on microglia, astrocytes, inflammatory cytokines, and inflammasomes have generated a burgeoning field in AD treatment research (Dourlen et al., 2019).”
BackgroundCalcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
Cascella, R., & Cecchi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094914 · Cited by 185
“However, the multifactorial nature of AD points out that the Aβ peptide might be required but not sufficient for the development of the disease [92].”
BackgroundOmics sciences for systems biology in Alzheimer’s disease: State-of-the-art of the evidence
Hampel, H., Nisticò, R., Seyfried, N. T., Levey, A. I., Modeste, E., Lemercier, P., Baldacci, F., Toschi, N., Garaci, F., Perry, G., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101346 · Cited by 144
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases
Ubeda-Bañon, I., Saiz-Sanchez, D., Flores-Cuadrado, A., Rioja-Corroto, E., Gonzalez-Rodriguez, M., Villar-Conde, S., Astillero-Lopez, V., Cabello-de la Rosa, J. P., Gallardo-Alcañiz, M. J., Vaamonde-Gamo, J., et al. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00200-7 · Cited by 123
“Although Alzheimer’s disease is mostly idiopathic (> 95% of patients suffer the sporadic form) [1], there is growing evidence of a genetic predisposition (60–80% attributable risk) [42].”
BackgroundSynaptic tau: A pathological or physiological phenomenon?
Robbins, M., Clayton, E., & Kaminski Schierle, G. S. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01246-y · Cited by 116
“For reviews on synaptic mechanisms of Tau pathology see [107, 346].”
BackgroundLi, Y., Fan, H., Sun, J., Ni, M., Zhang, L., Chen, C., Hong, X., Fang, F., Zhang, W., & Ma, P. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105747 · Cited by 117
PICALM and Alzheimer’s Disease: An Update and Perspectives
Ando, K., Nagaraj, S., Küçükali, F., de Fisenne, M.-A., Kosa, A.-C., Doeraene, E., Lopez Gutierrez, L., Brion, J.-P., & Leroy, K. (2022) · Cells · doi:10.3390/cells11243994 · Cited by 104
Marques-Coelho, D., Iohan, L. D. C. C., Melo de Farias, A. R., Flaig, A., The Brainbank Neuro–CEB Neuropathology Network, Letournel, F., Martin-Négrier, M.-L., Chapon, F., Faisant, M., Godfraind, C., et al. (2021) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-020-00052-5 · Cited by 101
Self-citationWan, T., Wang, Z., Luo, Y., Zhang, Y., He, W., Mei, Y., Xue, J., Li, M., Pan, H., Li, W., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8239642 · Cited by 100
“The amyloid beta (Aβ) and hyperphosphorylated tau protein are two key constituents of plaques and neurofibrillary tangles (NFTs) involved in the pathogenesis of AD [37].”
BackgroundMultiomics technologies: role in disease biomarker discoveries and therapeutics
Dar, M. A., Arafah, A. M., Bhat, K. A., Khan, A., Khan, M. S., Ali, A., Ahmad, S. M., Rashid, S. M., & Rehman, M. U. (2022) · Briefings in Functional Genomics · doi:10.1093/bfgp/elac017 · Cited by 113
Alzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 88
Step by step: towards a better understanding of the genetic architecture of Alzheimer’s disease
Lambert, J.-C., Ramirez, A., Grenier-Boley, B., & Bellenguez, C. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02076-1 · Cited by 87
“[83]).”
BackgroundSelf-citationSynaptic dysfunction in early phases of Alzheimer's Disease
(2022) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-819410-2.00022-9 · Cited by 83
Cabral-Pinto, M. M. S., Reis, A. P. M., Almeida, A. A., Pinto, E., Neves, O., Inácio, M., Gerardo, B., Freitas, S., Simões, M. R., Dinis, P. A., et al. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16224560 · Cited by 91
“Whilst the genetic component of sporadic AD risk has been increasingly recognized in recent years due to genome-wide association studies (GWAS) [18], the presence of the APOEε4 allele being the strongest genetic risk factor, the role of environmental exposures and the mechanisms of their contribution to the pathogenes…”
BackgroundGlaucoma as Neurodegeneration in the Brain
Chan, J. W., Chan, N. C. Y., & Sadun, A. A. (2021) · Eye and Brain · doi:10.2147/eb.s293765 · Cited by 98
“Several genes involved in regulating the metabolic pathways of amyloid precursor protein (APP) and amyloid-beta (Aβ) also control the post-translational modification of tau protein species.(2,3) Some AD genes, such as Apolipoprotein E (APOE), have been shown to increase the risk for POAG.”
BackgroundInfluentialCircular RNA Encoded Amyloid Beta peptides—A Novel Putative Player in Alzheimer’s Disease
Mo, D., Li, X., Raabe, C. A., Rozhdestvensky, T. S., Skryabin, B. V., & Brosius, J. (2020) · Cells · doi:10.3390/cells9102196 · Cited by 76
Valverde-Salazar, V., Ruiz-Gabarre, D., & García‐Escudero, V. (2023) · Antioxidants · doi:10.3390/antiox12071460 · Cited by 85
Selective Secretase Targeting for Alzheimer’s Disease Therapy
Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66
“AD pathology is characterized by the presence of two hallmark protein aggregations: amyloid-(cid:2) (A (cid:2) ) in plaques and phosphorylated tau in neurofibrillary tangles [4].”
Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOEε4 and Trem2*R47H
Kotredes, K. P., Oblak, A., Pandey, R. S., Lin, P. B.-C., Garceau, D., Williams, H., Uyar, A., O’Rourke, R., O’Rourke, S., Ingraham, C., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735524 · Cited by 66
Lambert, E., Saha, O., Soares Landeira, B., Melo de Farias, A. R., Hermant, X., Carrier, A., Pelletier, A., Gadaut, J., Davoine, L., Dupont, C., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01285-5 · Cited by 65
Self-citationThe path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases
Baldacci, F., Mazzucchi, S., Vecchia, A. D., Giampietri, L., Giannini, N., Koronyo‐Hamaoui, M., Ceravolo, R., Siciliano, G., Bonuccelli, U., Elahi, F. M., et al. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1731306 · Cited by 68
“logical aberrant pathway(s) – are shared across divergent brain diseases and phenotypes [265,267].”
BackgroundReview on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 72
The MAPT H1 Haplotype Is a Risk Factor for Alzheimer’s Disease in APOE ε4 Non-carriers
Sánchez‐Juan, P., Moreno–Grau, S., de Rojas, I., Hernández, I., Valero, S., Alegret, M., Montrreal, L., García‐González, P., Lage, C., López‐García, S., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00327 · Cited by 68
“Although recent genetic studies show that several AD GWASassociated genes, especially BIN1, are potentially involved in tau pathways (Dourlen et al., 2019), MAPT itself has not emerged until recently as a locus associated with AD.”
BackgroundResultIs γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi-Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 59
Ferrer, I., Andrés‐Benito, P., Ausín, K., Pamplona, R., del Río, J. A., Fernández‐Irigoyen, J., & Santamaría, E. (2021) · Brain Pathology · doi:10.1111/bpa.12996 · Cited by 65
Le Guen, Y., Luo, G., Ambati, A., Damotte, V., Jansen, I., Yu, E., Nicolas, A., de Rojas, I., Peixoto Leal, T., Miyashita, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2302720120 · Cited by 60
Guennewig, B., Lim, J., Marshall, L., McCorkindale, A. N., Paasila, P. J., Patrick, E., Kril, J. J., Halliday, G. M., Cooper, A. A., & Sutherland, G. T. (2021) · Scientific Reports · doi:10.1038/s41598-021-83872-z · Cited by 58
Eysert, F., Coulon, A., Boscher, E., Vreulx, A.-C., Flaig, A., Mendes, T., Hughes, S., Grenier-Boley, B., Hanoulle, X., Demiautte, F., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00926-w · Cited by 55
Self-citationOmics-based biomarkers discovery for Alzheimer's disease
Aerqin, Q., Wang, Z.-T., Wu, K., He, X., Dong, Q., & Yu, J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04614-6 · Cited by 58
Modifiable cardiovascular risk factors and genetics for targeted prevention of dementia
Rasmussen, I. J., & Frikke‐Schmidt, R. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad293 · Cited by 61
“An alternative suggestion is that the main driver of AD pathogenesis is focal adhesion defects in synapses with multiple entry points ultimately leading to synaptic dysregulation and consequently synapse loss and cognitive decline.(14)”
BackgroundYang, G., Huang, Y., Zheng, L., Zhang, L., Su, L., Wu, Y., Li, J., Zhou, L., Huang, J. Y., Tang, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111913 · Cited by 54
Park, J., Kim, H., Kim, J., & Cheon, M. (2020) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1008099 · Cited by 52
Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model
Wang, Y., Zhang, X., Song, Q., Hou, Y., Liu, J., Sun, Y., & Wang, P. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00598-2 · Cited by 56
“The genome-wide landscape of AD has been studied widely, and the gene expression patterns involved in in the process of AD have been described in detail [42, 43].”
BackgroundHampel, H., Lista, S., Neri, C., & Vergallo, A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101662 · Cited by 47
Tortorella, I., Argentati, C., Emiliani, C., Morena, F., & Martino, S. (2022) · Cells · doi:10.3390/cells11193093 · Cited by 52
“Kindlin-2 Required for FAs assembly and involved in ECM adhesion, Actin stabilization, and integrin-mediated signaling Gene downregulation AD [183,184]”
BackgroundSynapse vulnerability and resilience underlying Alzheimer’s disease
Taddei, R. N., & Duff, K. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105557 · Cited by 52
“29,32 Close associations have also been observed between the ApoE4 gene variant and synapse loss.”
Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
Wirths, O., & Zampar, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702972 · Cited by 44
“identified that might be involved in APP processing or βamyloid peptide generation [10].”
BackgroundPatel, A. G., Nehete, P. N., Krivoshik, S. R., Pei, X., Cho, E. L., Nehete, B. P., Ramani, M. D., Shao, Y., Williams, L. E., Wisniewski, T., et al. (2021) · Brain · doi:10.1093/brain/awab129 · Cited by 44
“Large-scale genome wide association studies (GWAS) have identified several innate immunity-related genes that are associated with an elevated risk for the development of late onset Alzheimer’s disease.(4,5) Many of these genes are highly expressed among microglia as regulators of phagocytic activity and inflammatory a…”
BackgroundEndosomal-lysosomal dysfunction in metabolic diseases and Alzheimer's disease
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.012 · Cited by 38
“The gradual, age-related lysosomal instability leads to gradual deposition of pathogenic protein species, slow disruption of microtubule-based transport processes, and progressive synaptic decline (see Bahr et al., 2012; Bendiske et al., 2002; Dourlen et al., 2019; Forner et al., 2017).”
BackgroundAlzheimer's Disease: Tau Pathology and Dysfunction of Endocytosis
Ando, K., Houben, S., Homa, M., de Fisenne, M.-A., Potier, M.-C., Erneux, C., Brion, J.-P., & Leroy, K. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.583755 · Cited by 39
“In view of the fact that most of the LOAD-related SNPs reside in noncoding regions of the genome, they are supposed to play a role in regulating gene expression.”
BackgroundInfluentialThe Mechanical Basis of Memory – the MeshCODE Theory
Goult, B. T. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.592951 · Cited by 39
Soheili‐Nezhad, S., van der Linden, R. J., Rikkert, M. G. M. O., Sprooten, E., & Poelmans, G. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12211 · Cited by 37
Role of the endolysosomal pathway and exosome release in tau propagation
Yan, M., & Zheng, T. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104988 · Cited by 36
Nanoparticle-Enabled Enrichment of Longitudinal Blood Proteomic Fingerprints in Alzheimer’s Disease
Hadjidemetriou, M., Rivers‐Auty, J., Papafilippou, L., Eales, J., Kellett, K. A. B., Hooper, N. M., Lawrence, C. B., & Kostarelos, K. (2021) · ACS Nano · doi:10.1021/acsnano.1c00658 · Cited by 36
Glennon, E. B. C., Lau, D. H. W., Gabriele, R. M. C., Taylor, M. F., Troakes, C., Opie-Martin, S., Elliott, C., Killick, R., Hanger, D. P., Perez‐Nievas, B. G., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa011 · Cited by 38
Dementia, infections and vaccines: 30 years of controversy
Ecarnot, F., Boccardi, V., Calcagno, A., Franceschi, C., Fülöp, T., Itzhaki, R. F., Michel, J., Panza, F., Rainero, I., Solfrizzi, V., et al. (2023) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02409-8 · Cited by 34
“Technological progress in genomics analysis has helped to reveal the huge range of genetic risk factors potentially implicated in AD [27], and there is a compelling need to move away from the concept of a single genetic factor, towards a convergent pathway that leads to dementia [28].”
Katsumata, Y., Fardo, D. W., Bachstetter, A. D., Artiushin, S., Wang, W., Wei, A. L., Brzezinski, L. J., Nelson, B. G., Huang, Q., Abner, E. L., et al. (2019) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz116 · Cited by 34
“A subset of slides were imaged on a Nikon C1 confocal microscope at 40 magnification using the following settings: (1) 2048 2048 pixel dimension; (2) 1.”
MethodGadhave, K., Gehi, B. R., Kumar, P., Xue, B., Uversky, V. N., & Giri, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03414-9 · Cited by 36
“Genome-wide association studies (GWAS) have reported more than 45 genes/loci potentially associated with the risk of AD development [14].”
BackgroundInfluentialOn the limits of graph neural networks for the early diagnosis of Alzheimer’s disease
Hernández‐Lorenzo, L., Hoffmann, M., Scheibling, E., List, M., Matías‐Guiu, J. A., & Ayala, J. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-21491-y · Cited by 34
Gerardo, B., Cabral-Pinto, M., Nogueira, J., Pinto, P., Almeida, A., Pinto, E., Marinho-Reis, P., Diniz, L., Moreira, P., Simões, M., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17176051 · Cited by 27
“Several factors have been reported as contributors to the development of sporadic AD—besides aging, genetics is another well-established risk factor, with the presence of the APOE ε4 allele being the strongest genetic elicitor of increased risk for the disease [9].”
BackgroundAutoantibodies targeting neuronal proteins as biomarkers for neurodegenerative diseases
Kocurova, G., Říčný, J., & Ovsepian, S. V. (2022) · Theranostics · doi:10.7150/thno.72126 · Cited by 31
Alzheimer’s Disease Genetics: Review of Novel Loci Associated with Disease
Tábuas‐Pereira, M., Santana, I. J., Guerreiro, R. J., & Brás, J. (2020) · Current Genetic Medicine Reports · doi:10.1007/s40142-020-00182-y · Cited by 30
Kilinc, D., Vreulx, A.-C., Mendes, T., Flaig, A., Coelho, D. M., Verschoore, M., Demiautte, F., Amouyel, P., Bank, N.-C. B., Eysert, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa139 · Cited by 37
“Several lines of evidence indicate that genetically driven synaptic failure may occur in Alzheimer’s disease (Dourlen et al., 2019) and, among the different genetic risk factors susceptible to be studied in our model, we focused on PTK2B, which has been already described to be involved in synaptic functions (Giralt et…”
BackgroundSelf-citationFani, L., Ahmad, S., Ikram, M. K., Ghanbari, M., & Ikram, M. A. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12212 · Cited by 30
The transcriptional landscape of Alzheimer’s disease and its association with Wnt signaling pathway
Martínez, M., & Inestrosa, N. C. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.029 · Cited by 26
α-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer’s disease
Agüero, P., Sainz, M. J., García‐Ayllón, M., Sáez‐Valero, J., Téllez, R., Guerrero, R., Pérez‐Pérez, J., Jiménez‐Escrig, A., & Gómez‐Tortosa, E. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00708-0 · Cited by 27
Khot, K. B., Gopan, G., Bandiwadekar, A., & Jose, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101806 · Cited by 29
The contribution of C. elegans neurogenetics to understanding neurodegenerative diseases
Liang, J., McKinnon, I. A., & Rankin, C. H. (2020) · Journal of Neurogenetics · doi:10.1080/01677063.2020.1803302 · Cited by 30
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment
Ke, J., Tian, Q., Xu, Q., Fu, Z., & Fu, Q. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.04.025 · Cited by 23
Molecular subtyping of Alzheimer’s disease with consensus non-negative matrix factorization
Zheng, C., & Xu, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250278 · Cited by 24
“A shift from Aβ-centered hypothesis to synapse-centered hypothesis has emerged [48, 49].”
BackgroundBIN1 and Alzheimer’s disease: the tau connection
Dourlen, P., Kilinc, D., Landrieu, I., Chapuis, J., & Lambert, J. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.03.004 · Cited by 28
“In addition, genetic and biological data clearly point to an interaction between tau and BIN1 at the patho-physiological level, and the synapse may be the natural site where this potential pathological interaction may manifest [88].”
Self-citationSoheili‐Nezhad, S., Jahanshad, N., Guelfi, S., Khosrowabadi, R., Saykin, A. J., Thompson, P. M., Beckmann, C. F., Sprooten, E., Zarei, M., & Neuroimaging, T. A. D. (2020) · Human Brain Mapping · doi:10.1002/hbm.25083 · Cited by 22
Genome-wide association study in Alzheimer’s disease: a bibliometric and visualization analysis
Zhang, J., Wang, Y., Zhang, Y., & Yao, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1290657 · Cited by 28
Jin, J., Zhang, H., Lu, Q., Tian, L., Yao, S., Lai, F., Liang, Y., Liu, C., Lu, Y., Tian, S., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00303 · Cited by 23
“The eventual development of Alzheimer’s disease in patients with TBI is influenced by multiple factors, including but not limited to environmental factors, age, and genetic susceptibility (Dourlen et al., 2019).”
Ma, Y., Ye, J., Zhao, L., & Pan, D. (2021) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20209665 · Cited by 23
“Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder of the elderly population, is a major global public health burden with over 26 million affected (1,2).”
BackgroundAssociation between WWOX/MAF variants and dementia-related neuropathologic endophenotypes
Dugan, A. J., Nelson, P. T., Katsumata, Y., Shade, L. M. P., Teylan, M., Boehme, K. L., Mukherjee, S., Kauwe, J. S. K., Hohman, T. J., Schneider, J. A., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.10.011 · Cited by 18
Schork, N. J., Elman, J. A., & Initiative, A. D. N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230548 · Cited by 25
“For example, the regulation cell junction and regulation protein tyrosine pathway-specific PRS we considered may capture effects of genes involved in synaptic functioning and cell signaling, consistent with studies suggesting this pathway is involved in AD-related cognitive decline [65, 66].”
Evaluating the association between genetically proxied ACE inhibition and dementias
Nassan, M. M., Daghlas, I., Piras, I. S., Rogalski, E. J., Reus, L. M., Pijnenburg, Y. A. L., Cuddy, L. K., Saxena, R., Mesulam, M. M., & Huentelman, M. J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13062 · Cited by 17
“44 Captopril, an ACE inhibitor that crosses the BBB, was shown to promote Aβ(1-42) brain deposition in an animal model of AD.”
BackgroundBumber, J. R., Rački, V., Mežnarić, S., Pelčić, G., & Mršić‐Pelčić, J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176047 · Cited by 24
“Over the past 15 years, approximately 75 loci that represent risk factors for AD progression have been found thanks to genome-wide association studies and sequencing projects [16,17,71–73].”
Dysregulation of the secretory pathway connects Alzheimer’s disease genetics to aggregate formation
Kuo, C., Chiang, A. W. T., Baghdassarian, H., & Lewis, N. E. (2021) · Cell Systems · doi:10.1016/j.cels.2021.06.001 · Cited by 21
Deng, Y., Li, W., Niu, L., Luo, X., Li, J., Zhang, Y. E., Liu, H., He, J., & Wan, W. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136209 · Cited by 17
Gunter, N. B., Gebre, R. K., Graff‐Radford, J., Heckman, M. G., Jack, C. R., Lowe, V. J., Knopman, D. S., Petersen, R. C., Ross, O. A., Vemuri, P., et al. (2024) · Neurology Genetics · doi:10.1212/nxg.0000000000200120 · Cited by 22
“40,41 Although CASS4 was identi fi ed as a susceptibility gene for clinically diagnosed AD dementia, our results are illuminating toward a mechanistic explanation by speci fi cally suggesting a relationship between APOE and CASS4 on in fl uencing amyloidosis.”
A unified model of dementias and age‐related neurodegeneration
Fossel, M. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12012 · Cited by 17
Immunotherapy Targeting Amyloid-ß Peptides in Alzheimer’s Disease
Zampar, S., & Wirths, O. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch2 · Cited by 27
“been linked to early-onset autosomal dominant forms of familial AD (FAD) with an early disease onset (13, 14), so far, only genetic risk loci have been identified as potentially involved in APP processing or β-amyloid peptide generation in sporadic cases (15).”
BackgroundLawingco, T., Chaudhury, S. R., Brookes, K. J., Guetta‐Baranes, T., Guerreiro, R. J., Brás, J., Hardy, J., Francis, P. T., Thomas, A. J., Belbin, O., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.11.009 · Cited by 20
Identification of key lipid metabolism-related genes in Alzheimer’s disease
Zeng, Y., Cao, S., Li, N., Tang, J., & Lin, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01918-9 · Cited by 20
“AD is linked to the pathophysiological mechanisms through the focal adhesion (FA) pathway, which integrates the physiological roles of amyloid precursor protein and tau [60].”
BackgroundGlaucoma as a Tauopathy—Is It the Missing Piece in the Glaucoma Puzzle?
Passaro, M. L., Matarazzo, F., Abbadessa, G., Pezone, A., Porcellini, A., Tranfa, F., Rinaldi, M., & Costagliola, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216900 · Cited by 16
“Recent evidence has reported that the A β protein plays a crucial role in controlling the post-translational modification of tau protein, promoting phosphorylation, and increasing the formation of tau species capable of aggregating in amorphous deposits and NFTs [91,93–95].”
BackgroundZhao, H., Li, S., Li, Z., Yang, S., Li, D., Zheng, J., Gao, H., Yun, L., Gu, Y., Li, L., et al. (2020) · Aging · doi:10.18632/aging.102970 · Cited by 15
“Synaptic loss occurs early during AD progression and is one of the first signs of the neurodegenerative process [19, 20].”
BackgroundMa, C., Hunt, J. B., Kovalenko, A., Liang, H., Selenica, M. B., Orr, M. B., Zhang, B., Gensel, J. C., Feola, D. J., Gordon, M. N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.628156 · Cited by 22
Yuan, B., Liu, M., Gong, Y., Wang, Z., Jin, X., Xie, G., Zhu, M., Zhang, X., Luo, S., Qu, Q., et al. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109448 · Cited by 16
Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease
Weninger, S. C., Sperling, B., Alexander, R., Ivarsson, M., Menzies, F. M., Powchik, P., Weber, C. J., Altar, C. A., Crystal, R. G., Haggarty, S. J., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12090 · Cited by 15
Galluzzi, S., Pievani, M., Zanetti, O. O., Benussi, L., The Italian-DIAfN Working Group, Frisoni, G. B., & Maria, E. D. (2022) · Biomedicines · doi:10.3390/biomedicines10123177 · Cited by 12
“Hence, over the last 12 years, up to 75 AD-associated genetic risk loci have been identified by genome-wide association studies (GWAS) and sequencing projects [4,17].”
BackgroundDeng, Y., Song, H., Yan, X., Zhao, Y. D., Chu, L., Ding, J., Shen, X., & Qi, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.868856 · Cited by 13
Barthelson, K., Pederson, S., Newman, M., Jiang, H., & Lardelli, M. T. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200279 · Cited by 13
“Early onset familial AD (EOfAD) cases have an age of onset before 65 years and arise due to mutations in the PRE-SENILIN genes ( PSEN1 and PSEN2 ), and the genes AMYLOID β A4 PRECURSOR PROTEIN ( A β PP ) and SORTILIN-RELATED RECEPTOR 1 ( SORL1 ) (reviewed in [8–10]).”
Youn, K., Ho, C., & Jun, M. (2023) · Marine Drugs · doi:10.3390/md21110580 · Cited by 11
Karima, S., Mahdavi, M., Rajaei, S., Lima, B. S., Ataeia, R., Tehrani, H. S., Baram, S. M., Tafakhori, A., Shateri, S., Fatemi, H., et al. (2021) · Galen Medical Journal · doi:10.31661/gmj.v10i0.1974 · Cited by 14
“Despite unknown etiology, different hypotheses have been attributed to AD pathologies such as the Aβ peptide cascade and neuroinflammation involvement [1-3].”
BackgroundOrhan, İ. E., Şenol, F. S., Salmas, R. E., Irmak, S., Özgün, Ö., Turgut, G. Ç., Şen, A., Zbancioc, A., Luca, S. V., Skiba, A., et al. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200315 · Cited by 13
“[26] In these studies, changes were found in some genes such as Clusterin (CLU), Bridging Integrator 1 (BIN1) and the ATP-Binding Cassette Transporter A7 (ABCA7), which are also linked to cholesterol metabolism and endocytosis.([27,28]) Increased BIN1, CLU and ABCA7 expression levels were associated with APP accumulat…”
Background(2024) · doi:10.1098/rsob.240185 · Cited by 9
“More recently, genome-wide association studies (GWAS) cast focal adhesion (FA) proteins in a central role in AD pathology [38,39], and knockdown of FA proteins significantly perturbs APP processing [40].”
InfluentialSelf-citationLi, X., Zhou, H., Yang, P., Shi, H., Xiong, Y., Nie, Z., Yu, J., Wang, Y., Zhou, R., & Wang, L. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.031 · Cited by 8
Zhang, Q., Liu, J., Liu, H., Ao, L., Yang, X., & Chen, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-54541-8 · Cited by 9
Ellis, C., Ward, N. L., Rice, M., Ball, N. J., Walle, P., Najdek, C., Kilinc, D., Lambert, J.-C., Chapuis, J., & Goult, B. T. (2024) · doi:10.1101/2024.03.04.583202 · Cited by 9
Self-citationOosterlynck, M., Leroux, É., Namasivayam, B., Bouillet, T., Caillierez, R., Loyens, A., Mazur, D., Perbet, R., Lefebvre, C., Aboulouard, S., et al. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00519-z · Cited by 11
“Notably, AD eLEVs contain proteins linked to platelet activation and FERMT2, a GWAS protein and mediator of the FA complex [61], which is known to stimulate astrogliosis and microglial activation.”
The proteostatic effects of traffic-derived air pollution on Alzheimer's disease risk
Kikis, E. A. (2020) · Open Biology · doi:10.1098/rsob.200146 · Cited by 8
Trumbore, C. N., & Raghunandan, A. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220622 · Cited by 8
“Yet, significant genetic data suggest that A plays a vital role in AD [15, 16].”
Background
Metadata
- Authors
- Dourlen, P., Kilinc, D., Malmanche, N., Chapuis, J., & Lambert, J.-C.
- Affiliations
- Inserm (FR)
- Corresponding author
- Lambert, Jean-Charles
- Venue
- Acta Neuropathologica
- Published
- 2019-04-13
- Volume
- 138
- Issue
- 2
- Pages
- 221-236
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC6660578
- OpenAlex
- W2936873828
- Cited by
- 168
- References
- 155
- Citations by year
- 2026: 4 · 2025: 19 · 2024: 11 · 2023: 14 · 2022: 35 · 2021: 40 · 2020: 30 · 2019: 15
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- LillOA (Université de Lille (University Of Lille)) (submittedVersion, other-oa)
- Funders
- Alzheimer's Association (BFG-14-318355)
- EU Joint Programme – Neurodegenerative Disease Research
- Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease
- Agence Nationale de la Recherche (ANR-11-LABX-0009, ANR-15-CE16-0002)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, genetic risk factors, amyloid hypothesis, amyloid precursor protein, amyloid-beta, tau pathology, innate immunity, focal adhesion pathway, synaptic plasticity, genome-wide association study, pathogenesis
- MeSH terms
- Exome Sequencing, Alzheimer Disease, Amyloid, Animals, Disease Models, Animal, Endocytosis, Humans, Models, Genetic, Models, Neurological, Neuronal Plasticity, Risk Factors, Synapses, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Neurofibrillary Tangles, tau Proteins, Genetic Predisposition to Disease, Focal Adhesions, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.